# FITWISE (NCT06518837)

> Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06518837
- Phase: PHASE2
- Status: RECRUITING
- Sponsor: Rutgers, The State University of New Jersey
- Conditions: Hormone Receptor-Positive Breast Cancer; HER2-Negative Breast Cancer
- Interventions: Tirzepatide
- Enrollment: 40
- Primary outcome: Weight Loss Reduction with Tirzepatide during Adjuvant Treatment for HR+/Her2- Breast Cancer (Measured by Body Weight Reduction)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=fitwise-nct06518837